1. Home
  2. RBNE vs APM Comparison

RBNE vs APM Comparison

Compare RBNE & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RBNE
  • APM
  • Stock Information
  • Founded
  • RBNE 2024
  • APM 2010
  • Country
  • RBNE Cyprus
  • APM United Kingdom
  • Employees
  • RBNE N/A
  • APM N/A
  • Industry
  • RBNE Marine Transportation
  • APM Biotechnology: Pharmaceutical Preparations
  • Sector
  • RBNE Consumer Discretionary
  • APM Health Care
  • Exchange
  • RBNE Nasdaq
  • APM Nasdaq
  • Market Cap
  • RBNE 7.3M
  • APM 18.9M
  • IPO Year
  • RBNE N/A
  • APM 2018
  • Fundamental
  • Price
  • RBNE $1.99
  • APM $2.64
  • Analyst Decision
  • RBNE
  • APM
  • Analyst Count
  • RBNE 0
  • APM 0
  • Target Price
  • RBNE N/A
  • APM N/A
  • AVG Volume (30 Days)
  • RBNE 498.0K
  • APM 20.0M
  • Earning Date
  • RBNE 09-02-2025
  • APM 04-30-2025
  • Dividend Yield
  • RBNE N/A
  • APM N/A
  • EPS Growth
  • RBNE N/A
  • APM N/A
  • EPS
  • RBNE N/A
  • APM N/A
  • Revenue
  • RBNE N/A
  • APM N/A
  • Revenue This Year
  • RBNE N/A
  • APM N/A
  • Revenue Next Year
  • RBNE N/A
  • APM N/A
  • P/E Ratio
  • RBNE N/A
  • APM N/A
  • Revenue Growth
  • RBNE N/A
  • APM N/A
  • 52 Week Low
  • RBNE $1.63
  • APM $0.46
  • 52 Week High
  • RBNE $20.57
  • APM $7.49
  • Technical
  • Relative Strength Index (RSI)
  • RBNE N/A
  • APM 59.96
  • Support Level
  • RBNE N/A
  • APM $1.26
  • Resistance Level
  • RBNE N/A
  • APM $4.47
  • Average True Range (ATR)
  • RBNE 0.00
  • APM 0.26
  • MACD
  • RBNE 0.00
  • APM 0.17
  • Stochastic Oscillator
  • RBNE 0.00
  • APM 43.87

About RBNE Robin Energy Ltd. Common Stock

Robin Energy Ltd operates a tanker vessel that engages in the transportation of refined petroleum products using its Handysize product tanker.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.

Share on Social Networks: